包膜挛缩手术治疗的新范式与算法:选择性应用脱细胞真皮基质
常规治疗首次、二次、三次复发成功率分别为72.5%、62.5%、50.0%,ADM为96.9%;按算法选择性使用ADM后总成功率85.6%,未遵循算法为64.2%(p<0.001)。
要点
- 双侧包膜挛缩和既往治疗失败分别使失败风险增加3.9倍和3.5倍。
- 选择性ADM用于双侧挛缩或单侧既往失败者,总成功率提升至85.6%。
- 常规治疗多次复发成功率递减,ADM单例成功率可达96.9%。
核心结论
- 选择性使用脱细胞真皮基质可将包膜挛缩总体治疗成功率提高至85%以上,单例可达近100%。
主要发现
- 常规治疗首次、二次、三次复发成功率分别为72.5%、62.5%、50.0%。
- 脱细胞真皮基质治疗成功率为96.9%。
- 双侧包膜挛缩使失败风险增加3.9倍,既往治疗失败增加3.5倍。
- 遵循算法选择性使用ADM时总成功率为85.6%,未遵循时为64.2%(p<0.001)。
关键数值与推荐
- 治疗成功定义为Baker II级或更好。
- 选择性ADM用于双侧包膜挛缩或单侧既往治疗失败者。
临床怎么用
- 对双侧包膜挛缩或单侧既往治疗失败者选择性使用ADM,可优化成功率并减少不必要的费用和手术时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Capsular contracture following breast augmentation is prone to recurrence with conventional surgical therapy. Adding acellular dermal matrix improves results but significantly increases operating time and cost. This study tested a new treatment algorithm that uses acellular dermal matrix selectively to optimize success rates while minimizing its drawbacks. METHODS: All patients surgically treated by the authors for Baker grade III/IV capsular contracture between 2007 and 2018 were included in this retrospective cohort study. Data were collected on patient, breast augmentation, capsular contracture, and surgical treatment characteristics, in addition to follow-up findings. Treatment success was defined as Baker grade II or better. RESULTS: One hundred eighty patients underwent 217 surgical treatments for capsular contracture. Conventional treatment was used in 185 cases and acellular dermal matrix in 32. Twenty-six patients were treated for a second occurrence and four were treated for a third. The average follow-up was 2.4 years. Conventional treatment was successful in 72.5 percent of first occurrences, 62.5 percent of second occurrences, and 50.0 percent of third occurrences. Acellular dermal matrix was successful in 96.9 percent of cases. The odds of failure were increased by bilateral capsular contracture (3.9 times) and previous treatment failure (3.5 times). When acellular dermal matrix was used selectively for bilateral capsular contracture or in unilateral cases with a previous treatment failure, the overall treatment success rate improved to 85.6 percent compared with 64.2 percent when this algorithm was not followed (p < 0.001). CONCLUSION: This study demonstrates that selective acellular dermal matrix use can increase success rate to over 85 percent in the overall treatment of capsular contracture, and to nearly 100 percent in individual cases.
引用
- Hidalgo DA, Weinstein AL. Surgical Treatment for Capsular Contracture: A New Paradigm and Algorithm. Plast Reconstr Surg. 2020. PMID: 32842102. doi:10.1097/PRS.0000000000007079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。